Search company, investor...

microLAN

microlan.nl

About microLAN

microLAN: from chemical analysers to Bioassays:It still is impossible to analyse all chemical substances, which are brought into nature by man. Scientists suggest there are around 100.000 dangerous chemical substances and even with instruments it is still not possible to detect them all. With the help of bioassays a much broader view of the possible dangerous effects can be analysed there where it is most important: nature itself!!With analytical / chemical testing only 5% can be detected, specially in waste and riverwater.Bioassays are more and more commonly used in combination with the traditional chemical analysers for the analyses of soil, water and sediment.

Headquarters Location

Biesbosweg 2

5145 PZ,

Netherlands

Missing: microLAN's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: microLAN's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

microLAN Patents

microLAN has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/10/2011

1/8/2013

USB, Computer buses, Linux distributions without systemd, Serial buses, Computer connectors

Grant

Application Date

2/10/2011

Grant Date

1/8/2013

Title

Related Topics

USB, Computer buses, Linux distributions without systemd, Serial buses, Computer connectors

Status

Grant

microLAN Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

microLAN Rank

microLAN Frequently Asked Questions (FAQ)

  • Who are microLAN's competitors?

    Competitors of microLAN include Amplyx Pharmaceuticals, Roka Bioscience, Life Technologies Corporation, Helix Therapeutics, Solidus Biosciences and 10 more.

Compare microLAN to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

M
Matrix Sensors

Matrix Sensors aims to democratize air quality sensors for a cleaner, healthier, and safer world.

ReaMetrix Logo
ReaMetrix

ReaMetrix, Inc. is a US and India-based biotechnology company aiming to provide high quality research and diagnostic assay solutions resulting in a transformation of the cost opportunities available in India into value for both the biotechnology and global health sectors. ReaMetrix's belief is that Indian resources will bring significant value to identifying and addressing the health care needs of the developing world, and that the resulting products will often translate into more affordable alternatives in the developed world.

M
McMillin Pharma

McMillin Pharma is a company seeking to market a high throughput screening method for testing drug libraries in early stage drug development. The technology and screening services of the company are used to predict which drugs may be more effective in later stages of the drug development process by modeling the interactions between tumors and their microenvironment.

T
Thermalin

Thermalin engineers new forms of insulin that will lower the burden of insulin use, increase patient adoption of and adherence to insulin therapy, improve patient lives and outcomes, and lower the cost of caring for people with Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).

N
Nanosep

Nanosep is a company with a new high performing environmentally friendly analytical technology to be used in the pharmaceutical and biotech industry. With the Nanosep technology, a customer can easily get results from complicated samples, such as blood plasma and pharmaceutical products. Both faster, with less effort and with higher precision compared to technologies available on the market today

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.